Primary prevention of cardiovacular disease: Managing hypertension and hyperlipidaemia

Heart

Volumn 90, Issue SUPPL. 4, 2004, Pages

  Hobbs, F D R ^a   Cowie, ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; LIPID;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; DATA ANALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; ATTITUDE TO HEALTH; DRUG COMBINATION; PUBLIC OPINION; REVIEW; RISK FACTOR;

ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; PUBLIC OPINION; RISK FACTORS;

EID: 2442659394     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. National High Blood Pressure Education Program Working Group. Report on primary prevention of hypertension. Arch Intern Med 1993;153:186-208.
2. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet 1986;ii:933-6.
3. Haffner SM, Lento S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-83.
5. Collins R, Peto R, Macmahon S, et al. Blood pressure, stroke, and coronary artery disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
7. UK Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
8. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995;274:131-6.
9. Brady AJB, Betteridge DJ. Prevalence and risks of undertreatment with statins. Br J Cardiol 2003;10:218-9.
10. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001;38:827-32.
11. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines; a comparison or EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
12. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000;321:1322-5.
13. Erhardt L, Hobbs FDR. Public perceptions of cardiovascular risk in five European countries: the REACT study. Int J Clin Pract 2002;56:638-44.
14. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey. Fam Pract 2002;19:596-604.
15. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-29.